AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 78_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 1Group_NNP operating_NN profit_NN Before_IN exceptional_JJ Exceptional_JJ 2004_CD items_NNS items_NNS Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD Group_NNP turnover_NN 21,426_CD 21,426_CD Operating_NN costs_NNS Cost_NN of_IN sales_NNS 5,150_CD 5,150_CD Distribution_NN costs_VBZ 177_CD 177_CD Research_NNP and_CC development_NN 3,803_CD 3,803_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 7,841_CD 7,841_CD 16,971_CD 16,971_CD Other_JJ operating_NN income_NN Royalties_NNP 95_CD 95_CD Other_JJ income_NN 220 220 315 315_CD Cost_NN of_IN sales_NNS includes_VBZ charges_NNS against_IN stock_NN and_CC prepayments_NNS in_IN respect_NN of_IN Exanta_NNP and_CC Iressa_NNP totalling_VBG $_$ 195m_CD ._.
Other_JJ income_NN includes_VBZ gains_NNS arising_VBG from_IN disposals_NNS under_IN ongoing_JJ product_NN and_CC investment_NN rationalisation_NN programs_NNS ._.
Group_NNP operating_NN profit_NN 4,770_CD 4,770_CD Charges_NNS included_VBD above_IN for_IN depreciation_NN 916_CD 916_CD for_IN amortisation_NN 311_CD 311_CD for_IN impairment_NN 41_CD 41_CD Gross_NNP profit_NN ,_, as_IN defined_VBN by_IN the_DT Companies_NNS Act_NNP 1985_CD 16,276_CD 16,276_CD The_DT charge_NN for_IN impairment_NN arises_VBZ from_IN writing_VBG off_RP fixed_JJ assets_NNS and_CC goodwill_NN associated_VBN with_IN Iressa_NNP and_CC Exanta_NNP ._.
